My watch list
my.bionity.com  
Login  

Roche Announces Thomas Schinecker as New President of 454 Life Sciences

18-07-2011: 454 Life Sciences, a center of excellence of Roche’s business unit Applied Science,  announced that effective August 1, 2011, Dr. Thomas Schinecker is appointed Lifecycle Leader for Sequencing and President of 454 Life Sciences, Inc., in Branford, Connecticut, USA, reporting to Robert Yates, Head of Applied Science.

Dr. Schinecker is currently the Diagnostics General Manager of Sweden, located in Bromma, a suburb of Stockholm.  Dr. Schinecker’s extensive background and experience of over eight years at Roche will be instrumental in guiding 454 Life Sciences into the next generation of pyrosequencing. Dr. Schinecker holds a PhD in oncology, studying at the New York University. He then excelled in several leadership positions in the Sales & Marketing organization of Roche Diagnostics Austria, starting his career at Roche in the Perspectives Program in 2003. With his success in several key management positions within Roche Diagnostics, Dr. Schinecker brings the required organizational and operating skills to 454 Life Sciences’ highly innovative and accurate long sequence read technology. 454 Sequencing Systems are used productively by large numbers of life science researchers in cancer, infectious disease, immunogenetics, drug discovery, agriculture and other disciplines, resulting in more than 1,000 peer-reviewed publications.

Facts, background information, dossiers
More about 454 Life Sciences
More about Roche
  • News

    Roche and Molecular Partners enter into alliance

    Roche and Molecular Partners AG announced that they have entered  into a research collaboration and licensing agreement to discover, develop and commercialize several proprietary therapeutics incorporating Molecular Partners’ DARPin® biologics conjugated to toxic agents developed at Roche f ... more

    immatics and Roche sign cancer vaccine and immunotherapy collaboration

    immatics biotechnologies GmbH and Roche announced a strategic research and development collaboration covering multiple cancer vaccines and immunotherapeutics. The agreement will focus on the research, clinical development and commercialisation of a number of new tumour-associated peptide (T ... more

    Polyphor and Roche join effort to combat multidrug-resistant bacterial infections

    Polyphor Ltd and Roche announced that they have entered into an exclusive worldwide license agreement to develop and commercialize Polyphor’s investigational macrocycle antibiotic, POL7080, for patients suffering from bacterial infections caused by Pseudomonas aeruginosa. Under the terms of ... more

  • Companies

    Roche Austria GmbH

    Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche i ... more

    Roche Deutschland Holding GmbH

    more

More about Roche Diagnostics
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE